CN107343878A - A kind of Peramivir lipid microsphere injection and preparation method thereof - Google Patents
A kind of Peramivir lipid microsphere injection and preparation method thereof Download PDFInfo
- Publication number
- CN107343878A CN107343878A CN201610284844.2A CN201610284844A CN107343878A CN 107343878 A CN107343878 A CN 107343878A CN 201610284844 A CN201610284844 A CN 201610284844A CN 107343878 A CN107343878 A CN 107343878A
- Authority
- CN
- China
- Prior art keywords
- peramivir
- preparation
- lipid microsphere
- water
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of safe, stable Peramivir lipid microsphere injection being injected intravenously and preparation method thereof, it is by 1 part of Peramivir, 20 parts of ethyl oleates, 7.3 parts of Emulsifier EL-60s, 10 parts of niacinamide, 4.2 parts of sodium sulfites, 0.75 part of polysorbate and water for injection composition.The lipid microsphere injection considerably increases the stability of Peramivir, and preparation technology is simple, high income, redissolves good.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, and in particular to a kind of safe, stable Peramivir lipid microsphere injection
And preparation method thereof, belong to field of medicine preparations.
Background technology
Peramivir is a kind of new anti-influenza virus medicament, belongs to neuraminidase inhibitor, existing clinical test card
It is bright effective to A type and influenza B.According to the circular of the World Health Organization, H7N9 belongs to subtypes of influenza A virus, preliminary examination
Test result to show, neuraminidase inhibitor works to the virus.Peramivir is a kind of cyclopentane derivatives, is connected with ring
Group have hydrophilic carboxyl and guanidine radicals, and hydrophobic isopentyl and acetylamino, 4 different groups of polarity act on respectively
The different active site region in influenza virus NA structures, strong inhibition NA activity.However, the limit of impurities is high, the term of validity is short,
The production storage of this medicine in the industrial production is constrained, if the initial impurity that can be reduced in preparation is horizontal, in current matter
Under the limit of impurities requirement of amount standard, the product effect phase can be extended, more meet industry and clinical needs.
Because the pharmacological action of Peramivir is extensive, the demand and method of administration of its clinical application also expand day by day, because
A kind of this impurity of exploitation is few, and the preparation that the term of validity is long, technique simple and stable and adverse reaction are small is extremely necessary.
The present inventor passes through long-term research, it was thus unexpectedly found that is dispensed using lipid microspheres technology by being spray-dried
Injection is made, can solve the problem that the problem of flucloxacillin sodium quality is unstable, obtains more preferable Clinical practice effect, thus completes
The present invention.
The content of the invention
It is an object of the invention to provide a kind of Peramivir lipid microsphere injection, is that one kind is added pharmaceutically by active component
The emulsion liquid preparation that acceptable auxiliary material is prepared, addition metal ion chelation agent can be carried effectively in preparation prescription
High yield quality, reduce the degraded of active component and auxiliary material.
It is to provide and a kind of Peramivir lipid microsphere injection is provided, it is combined Peramivir by certain supplementary material
Lipid microspheres are made, it is aseptic subpackaged to be made, the stability of Peramivir is considerably increased, preparation technology is simple, high income, redissolves good
It is good.
Peramivir lipid microsphere injection provided by the invention is composed of the following components：
It is composed of the following components：1 part of Peramivir, 17-21 part ethyl oleates, 5-7.5 part Emulsifier EL-60 8-11.2 parts
Niacinamide, 4-5 part sodium sulfites, 0.5-0.9 part polysorbates, water for injection add to 1000ml.
It is a further object to provide a kind of preparation method of described Peramivir lipid microsphere injection, mainly
It is related to pH control methods therein and sterilizing methods, i.e., before the pH regulations of preparation being placed in into two oil, water mixing, passes through control
The pH that aqueous phase pH settles control final preparation at one go is qualified；Terminal sterilization selection sterilising temp >=123 DEG C, sterilization time≤
6min.Realized especially by following steps：
（1）Peramivir, Emulsifier EL-60, niacinamide is taken to be added in ethyl oleate, in 65-73 DEG C of stirring and dissolving, system
Into oil phase；
（2）Sodium sulfite, polysorbate is taken to add in water for injection, it is 9.5 to adjust aqueous phase pH values with pH values conditioning agent, is mixed
After be heated to 65-73 DEG C of temperature, as aqueous phase；
（3）Aqueous phase obtained above is slowly instilled in oil phase under agitation, 10-30min, Ran Houzhuan are stirred after dripping off
Move to high speed homogenizer high speed to stir 3-5 times, each 5-10min, obtain homogeneous white " milky " liquid；
（4）Will（3）Obtained white " milky " liquid, 65-73 DEG C of water for injection is added to 1000ml, high pressure microjet is moved into after mixing
Homogeneous in nano-dispersed instrument, the emulsion that average grain diameter is 250-380nm is made；
（5）Obtained emulsion is filtered, nitrogen charging, embedding, sterilized in rotary water-bath sterilization cabinet, sterilising temp >=
121 DEG C, sterilize duration≤5min, overall sterilization process F0 >=8, produces Peramivir lipid microsphere injection.
Sterilized 2 minutes it is preferred that sterilising conditions are 127 DEG C, 125 DEG C of sterilizings sterilize 5 minutes for 3 minutes and 124 DEG C, selection rotation
Formula sterilizes or non-rotating sterilizing.
The preferable technical recipe consumption proportion of the inventive method and aqueous phase pH are：1 part of Peramivir, 20 parts of ethyl oleates,
7.3 parts of Emulsifier EL-60s, 10 parts of niacinamide, 4.2 parts of sodium sulfites, 0.75 part of polysorbate, water for injection add to
1000ml, it is 124 DEG C to carry out damp and hot rotation sterilising temp, sterilization time 3.5min, F0 value >=8.
PH adjusting agent is selected from the mixing of one or both of sodium hydroxide, hydrochloric acid, phosphate, citric acid or sodium citrate
Thing, preferably sodium hydroxide, addition opportunity of pH adjusting agent are in before water-oil phase starts mixing, and regulation aqueous pH values are
9.5, you can prepare qualified, the stable Peramivir lipid microsphere injection that final preparation pH is 4-6.
Peramivir lipid microsphere injection prepared by the present invention, the metal ions such as natrium adetate are mainly added in prescription
Complexing agent, procedure of pH adjustment is preposition, using the high temperature, short time sterilizing methods of novelty, Peramivir lipid microspheres prepared by this mode
Injection, active component and auxiliary material less degradation, particle diameter distribution is narrow, and the stability of preparation substantially increases.
The lipid microsphere injection of the present invention has advantages below：（1）Slow releasing function with stable uniform：Active component
Slowly release, delays renal excretion and metabolism, so as to extend action time, improves mass effect；（2）Increase the dissolubility of medicine,
Improve the bioavilability of preparation；（3）With the protective effect to active pharmaceutical ingredient, ginkolide B not open loop, improve
Stability, reduce toxic side effect；（4）Good envelop rate and extremely low slip, and significant stability enhancing.The present invention
Peramivir lipid microsphere injection is that a kind of impurity is few, the preparation that the term of validity is long, technique simple and stable and adverse reaction are small.
Embodiment
The present invention with the following Examples, is described in further detail, but it not carries out any restrictions to the present invention.
Embodiment 1
（1）Weigh 300mg Peramivirs, 2.21g Emulsifier EL-60s, 3g niacinamide and 6g ethyl oleates and add container
In, be dispersed to dissolving using high-speed shearing machine, form oil phase, and be heated to 65-73 DEG C it is standby；
（2）Take 1.26g sodium sulfites, 0.23g polysorbates to add in water for injection, be with sodium hydroxide regulation aqueous phase pH values
9.5, it is standby that 65-73 DEG C of temperature is heated to after mixing；
（3）Under nitrogen protection, aqueous phase obtained above is slowly instilled in oil phase under agitation, aqueous phase is into oil phase
Rate of addition is 5-10ml/min, and 25min is stirred after dripping off, and is then transferred to high speed homogenizer high speed stirring 3-5 times, every time
5-10min, obtain homogeneous white " milky " liquid；
（4）Will（3）Obtained white " milky " liquid, 65-73 DEG C of water for injection 1000ml is added, high pressure microjet is moved into after mixing and is received
Homogeneous in rice separating apparatus, the emulsion that average grain diameter is 250-380nm is made；
（5）Obtained emulsion is filtered, nitrogen charging, embedding, sterilized in rotary water-bath sterilization cabinet, in 127 DEG C of sterilizings
2min is produced.
Embodiment 2
（1）Weigh 300mg Peramivirs, 2.25g Emulsifier EL-60s, 2.4g niacinamide and 6.3g ethyl oleates and add and hold
In device, be dispersed to dissolving using high-speed shearing machine, form oil phase, and be heated to 65-73 DEG C it is standby；
（2）Take 1.5g sodium sulfites, 0.15g polysorbates to add in water for injection, be with sodium hydroxide regulation aqueous phase pH values
9.5, it is standby that 65-73 DEG C of temperature is heated to after mixing；
（3）Under nitrogen protection, aqueous phase obtained above is slowly instilled in oil phase under agitation, stirred after dripping off
25min, rate of addition of the aqueous phase into oil phase are 5-10ml/min, are then transferred to high speed homogenizer high speed and stir 3-5 times,
Each 5-10min, obtain homogeneous white " milky " liquid；
（4）Will（3）Obtained white " milky " liquid, 65-73 DEG C of water for injection 1000ml is added, high pressure microjet is moved into after mixing and is received
Homogeneous in rice separating apparatus, the emulsion that average grain diameter is 250-380nm is made；
（5）Obtained emulsion is filtered, nitrogen charging, embedding, sterilized in rotary water-bath sterilization cabinet, in 125 DEG C of sterilizings
3min is produced.
Embodiment 3
（1）Weigh 300mg Peramivirs, 1.5g Emulsifier EL-60s, 3.4g niacinamide and 5.1g ethyl oleates and add and hold
In device, be dispersed to dissolving using high-speed shearing machine, form oil phase, and be heated to 65-73 DEG C it is standby；
（2）Take 1.2g sodium sulfites, 0.27g polysorbates to add in water for injection, be with sodium hydroxide regulation aqueous phase pH values
9.5, it is standby that 65-73 DEG C of temperature is heated to after mixing；
（3）Under nitrogen protection, aqueous phase obtained above is slowly instilled in oil phase under agitation, aqueous phase is into oil phase
Rate of addition is 5-10ml/min, and 25min is stirred after dripping off, and is then transferred to high speed homogenizer high speed stirring 3-5 times, every time
5-10min, obtain homogeneous white " milky " liquid；
（4）Will（3）Obtained white " milky " liquid, 65-73 DEG C of water for injection 1000ml is added, high pressure microjet is moved into after mixing and is received
Homogeneous in rice separating apparatus, the emulsion that average grain diameter is 250-380nm is made；
（5）Obtained emulsion is filtered, nitrogen charging, embedding, sterilized in rotary water-bath sterilization cabinet, in 124 DEG C of sterilizings
5min is produced.
Comparative example 1
（1）Weigh 300mg Peramivirs, 2.21g Emulsifier EL-60s, 3g niacinamide and 6g ethyl oleates and add container
In, be dispersed to dissolving using high-speed shearing machine, form oil phase, and be heated to 65-73 DEG C it is standby；
（2）1.26g sodium sulfites are taken to add in water for injection, it is 9.5 to adjust aqueous phase pH values with sodium hydroxide, is heated after mixing
It is standby to 65-73 DEG C of temperature；
（3）Under nitrogen protection, aqueous phase obtained above is slowly instilled in oil phase under agitation, stirred after dripping off
25min, rate of addition of the aqueous phase into oil phase are 5-10ml/min, are then transferred to high speed homogenizer high speed and stir 3-5 times,
Each 5-10min, obtain homogeneous white " milky " liquid；
（4）Will（3）Obtained white " milky " liquid, 65-73 DEG C of water for injection 1000ml is added, high pressure microjet is moved into after mixing and is received
Homogeneous in rice separating apparatus, the emulsion that average grain diameter is 250-380nm is made；
（5）Obtained emulsion is filtered, nitrogen charging, embedding, sterilized in rotary water-bath sterilization cabinet, in 125 DEG C of sterilizings
2min is produced.
Comparative example 2
（1）Weigh 300mg Peramivirs, 2.21g Emulsifier EL-60s, 3g niacinamide and 6g ethyl oleates and add container
In, be dispersed to dissolving using high-speed shearing machine, form oil phase, and be heated to 65-73 DEG C it is standby；
（2）Take 1.26g sodium sulfites, 0.23g polysorbates to add in water for injection, be with sodium hydroxide regulation aqueous phase pH values
9.5, it is standby that 65-73 DEG C of temperature is heated to after mixing；
（3）Under nitrogen protection, aqueous phase obtained above is poured into oil phase under agitation, 25min is stirred, is then transferred to
High speed homogenizer high speed stirs 3-5 times, each 5-10min, obtains white " milky " liquid；
（4）Will（3）Obtained white " milky " liquid, 65-73 DEG C of water for injection 1000ml is added, high pressure microjet is moved into after mixing and is received
Homogeneous in rice separating apparatus, the emulsion that average grain diameter is 250-380nm is made；
（5）Obtained emulsion is filtered, nitrogen charging, embedding, sterilized in rotary water-bath sterilization cabinet, in 125 DEG C of sterilizings
2min is produced.
Comparative example 3
（1）Weigh 300mg Peramivirs, 2.21g Emulsifier EL-60s and 6g ethyl oleates to add in container, using at a high speed
Cutter be dispersed to dissolving, forms oil phase, and be heated to 65-73 DEG C it is standby；
（2）Take 1.26g sodium sulfites, 0.23g polysorbates to add in water for injection, be with sodium hydroxide regulation aqueous phase pH values
9.5, it is standby that 65-73 DEG C of temperature is heated to after mixing；
（3）Under nitrogen protection, aqueous phase obtained above is slowly instilled in oil phase under agitation, stirred after dripping off
25min, rate of addition of the aqueous phase into oil phase are 5-10ml/min, are then transferred to high speed homogenizer high speed and stir 3-5 times,
Each 5-10min, obtain homogeneous white " milky " liquid；
（4）Will（3）Obtained white " milky " liquid, 65-73 DEG C of water for injection 1000ml is added, high pressure microjet is moved into after mixing and is received
Homogeneous in rice separating apparatus, the emulsion that average grain diameter is 250-380nm is made；
（5）Obtained emulsion is filtered, nitrogen charging, embedding, sterilized in rotary water-bath sterilization cabinet, in 110 DEG C of sterilizings
10min is produced.
The form of the lipid microspheres of test example 1, particles size and distribution
The form of lipid microspheres, particles size and distribution are to ensure that medicine plays to answer an effective important ring.Using corrected band
The particle diameter of lipid microspheres prepared by the light microscope determining embodiment of the present invention 1-3 and comparative example 1-3 of eyepiece micrometer.
The particle diameter of 1-3 of embodiment of the present invention product 80% is less than 300nm, all between 250-380nm, form
For the spherical or oval spheroid of rounding, it is evenly distributed.
The particle diameter of comparative example 1-3 product 90% is more than 500nm, and form is irregular, and distribution is disorderly and unsystematic.
The measure of the envelop rate of test example 2
By the ginkgolide B lipid microsphere injection prepared in embodiment 1-3 and comparative example 1-3 with 5000r/min rotating speed high speed
Centrifugation, centrifuge 20 minutes, take supernatant, dissolved with methanol, HPLC methods survey ginkolide B content, computational envelope rate, as a result show
In table 1 below.
The entrapment efficiency determination result of table 1
| Numbering | Embodiment 1 | Embodiment 2 | Embodiment 3 | Comparative example 1 | Comparative example 2 | Comparative example 3 |
| Envelop rate | 98.7% | 99.1% | 97.2% | 87.7% | 91.2% | 84.3% |
As shown in Table 1, the envelop rate of fat micro sphere preparation prepared by embodiment 1-3 is significantly higher than comparative example 1-3 lipid microspheres system
The envelop rate of agent.Illustrate when the composition beyond using composition used in the present invention, or limited when Ingredient Amount in the present invention
When outside Ingredient Amount scope, the lipid microspheres envelop rate of gained lipid microspheres is less than the present invention.Further, in envelop rate,
In comparative example 1-3, comparative example 3 is worst, illustrates that the material that the present invention limits is optimal.
The study on the stability of test example 3
1-3 of the embodiment of the present invention samples prepared are respectively placed under conditions of 40 DEG C of high temperature, relative humidity 75% 6 months,
Accelerated test investigation is carried out, experimental result is shown in table 2 below.
The accelerated test result of table 2
As shown in Table 2, when accelerating June, comparative example content reduces, relevant material rise；And sample property, the content of the present invention
Change equal unobvious with relevant material, illustrate that the product stability of the present invention is good, further illustrate what the present invention was limited
Material is optimal, and the Peramivir that fat micro sphere preparation of the present invention is encapsulated will not the relevant material of open loop generation.
Pass through the result of multiplicity above-described embodiment and experimental example, it was confirmed that combination of the invention has association
Same-action effect, Peramivir lipid microspheres of the invention have good outward appearance, and particle is small, uniform particle sizes, and envelop rate is high, surely
Qualitative height, percolation ratio is low, has good industrial application value.
The present invention is described in detail above by embodiment and embodiment, it will nevertheless be understood that these are said
It is bright any restrictions not to be formed to the scope of the present invention, in the case of without departing from the spirit and scope of protection of the present invention, can be with
Technical solutions and their implementation methods of the present invention are carried out with a variety of modifications, improves and replaces, these are because of the guarantor for falling into the present invention
In the range of shield.
Claims (6)
1. a kind of Peramivir lipid microsphere injection, it is characterised in that composed of the following components：1 part of Peramivir, 17-21 parts
Ethyl oleate, 5-7.5 part Emulsifier EL-60s, 8-11.2 part niacinamide, 4-5 part sodium sulfites, the poly- sorb of 0.5-0.9 parts
Ester, appropriate water for injection.
2. the preparation method of a kind of Peramivir lipid microsphere injection according to claim 1, it is characterised in that pass through
Following steps are realized：
（1）Peramivir, Emulsifier EL-60, niacinamide is taken to be added in ethyl oleate, in 65-73 DEG C of stirring and dissolving, system
Into oil phase；
（2）Sodium sulfite, polysorbate is taken to add in water for injection, it is 9.5 to adjust aqueous phase pH values with pH values conditioning agent, is mixed
After be heated to 65-73 DEG C of temperature, as aqueous phase；
（3）Aqueous phase obtained above is slowly instilled in oil phase under agitation, 10-30min, Ran Houzhuan are stirred after dripping off
Move to high speed homogenizer high speed to stir 3-5 times, each 5-10min, obtain homogeneous white " milky " liquid；
（4）Will（3）Obtained white " milky " liquid, 65-73 DEG C of water for injection is added to 1000ml, high pressure microjet is moved into after mixing
Homogeneous in nano-dispersed instrument, the emulsion that average grain diameter is 250-380nm is made；
（5）Obtained emulsion is filtered, nitrogen charging, embedding, sterilized in rotary water-bath sterilization cabinet, sterilising temp >=
121 DEG C, sterilize duration≤5min, overall sterilization process F0 >=8, produces Peramivir lipid microsphere injection.
A kind of 3. preparation method of Peramivir lipid microsphere injection according to claim 2, it is characterised in that step
（2）The pH values conditioning agent is selected from the mixing of one or both of sodium hydroxide, hydrochloric acid, phosphate, citric acid or sodium citrate
Thing.
A kind of 4. preparation method of Peramivir lipid microsphere injection according to claim 2 or 3, it is characterised in that
Step（2）The addition timing of pH conditioning agents is before water-oil phase starts mixing.
A kind of 5. preparation method of Peramivir lipid microsphere injection according to Claims 2 or 3, it is characterised in that water
Rate of addition in opposite oil phase is 5-10ml/min.
A kind of 6. preparation method of Peramivir lipid microsphere injection according to claim 2 or 3, it is characterised in that
Step（5）Sterilising conditions are：127 DEG C sterilize 2 minutes, and 124 DEG C of sterilizings sterilize 5 minutes for 3.5 minutes and 122 DEG C, and selection is rotary
Sterilizing or non-rotating sterilizing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610284844.2A CN107343878A (en) | 2016-05-04 | 2016-05-04 | A kind of Peramivir lipid microsphere injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610284844.2A CN107343878A (en) | 2016-05-04 | 2016-05-04 | A kind of Peramivir lipid microsphere injection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107343878A true CN107343878A (en) | 2017-11-14 |
Family
ID=60253111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610284844.2A Pending CN107343878A (en) | 2016-05-04 | 2016-05-04 | A kind of Peramivir lipid microsphere injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107343878A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114177135A (en) * | 2022-01-04 | 2022-03-15 | 朗天药业(湖北)有限公司 | Peramivir pharmaceutical composition and preparation method thereof |
-
2016
- 2016-05-04 CN CN201610284844.2A patent/CN107343878A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114177135A (en) * | 2022-01-04 | 2022-03-15 | 朗天药业(湖北)有限公司 | Peramivir pharmaceutical composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Encapsulation of curcumin using fucoidan stabilized zein nanoparticles: Preparation, characterization, and in vitro release performance | |
| CN107213470B (en) | Tylosin tartrate soluble powder and preparation method thereof | |
| CN104434786B (en) | Stable bromhexine hydrochloride sodium chloride injection composition | |
| CN106692124A (en) | Acetylcysteine pharmaceutical composition and preparation method thereof | |
| CN104721155B (en) | A kind of temozolomide freeze-dried powder preparation and preparation method thereof | |
| CN106606476A (en) | Ibuprofen suspension drops and preparation method thereof | |
| CN106619163A (en) | Glabridin nanosuspension and preparation method thereof | |
| CN103961311A (en) | Heparin sodium injection and preparation method thereof | |
| CN106075414A (en) | A kind of bromelain liposome and preparation method thereof | |
| CN106074387B (en) | With thixotropic Triamcinolone acetonide nasal spray and preparation method thereof | |
| CN107343878A (en) | A kind of Peramivir lipid microsphere injection and preparation method thereof | |
| CN104666312B (en) | Preparation containing Calcipotriol and dipropium dipropionate | |
| CN107595782A (en) | A kind of Linezolid dry suspensoid agent and preparation method thereof | |
| CN104940136B (en) | The production method of compound fluocinonide tincture and prepared compound fluocinonide tincture | |
| CN105106108B (en) | Supermolecule control slow-release salicylic acid formula and its technology of preparing | |
| CN103948564B (en) | A kind of lyrica capsule and preparation method thereof | |
| CN107982240B (en) | Potassium sodium dehydroandroan drographolide succinate enteric coated granules capable of being accurately dissolved out and preparation method thereof | |
| CN107362142B (en) | Fulvestrant liposome injection and preparation method thereof | |
| CN105476954B (en) | A kind of lomefloxacin hydrochloride injection and preparation method | |
| CN107343876A (en) | A kind of clevidipine lipid microsphere injection and preparation method thereof | |
| CN105287366B (en) | A kind of vitamin K 1 injection and preparation method thereof | |
| CN107343874A (en) | A kind of dexamethasone sodium phosphate lipid microsphere injection and preparation method thereof | |
| CN106389359A (en) | Belinostat medicine composition for injection and preparation method thereof | |
| CN113952296B (en) | Preparation method of compound sulfamethoxazole injection | |
| CN107854444A (en) | A kind of terazosin and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171114 |
|
| WD01 | Invention patent application deemed withdrawn after publication |